Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Names Regenauer Global OTC Head, Underscores Consumer Focus

This article was originally published in The Tan Sheet

Executive Summary

Sanofi-Aventis further highlights its consumer health focus by naming Hans Regenauer to head its global OTC business as the firm works to close its acquisition of OTC and personal care firm Chattem

You may also be interested in...



Sanofi Mulls Putting Cash Behind Interest In Buying L’Oreal’s Shares

Sanofi has the cash to buy back about $12 billion of its shares currently owned by beauty firm L’Oreal, if those shares were up for sale, Sanofi CEO Viehbacher says. L’Oreal CEO Agon suggested in recent earnings call that the firm could seek cash for future deals through the sale of its 9% stake in Sanofi.

Sanofi Mulls Putting Cash Behind Interest In Buying L’Oreal’s Shares

Sanofi has the cash to buy back about $12 billion of its shares currently owned by beauty firm L’Oreal, if those shares were up for sale, Sanofi CEO Viehbacher says. L’Oreal CEO Agon suggested in recent earnings call that the firm could seek cash for future deals through the sale of its 9% stake in Sanofi.

Sanofi completes Chattem deal

Sanofi-Aventis completes its purchase of Chattanooga, Tenn-based Chattem, giving the French firm a strong base for its growth in the U.S. consumer health care market, which represents 25 percent of the worldwide opportunity. Sanofi said March 11 that effective at the close of business on March 10, Chattem's common stock ceased trading on NASDAQ. The deal provides new channels for Sanofi to maximize the potential of switching prescription drugs to OTC products, beginning with its Rx antihistamine Allegra (1"The Tan Sheet" Jan. 4, 2010). Chattem's former CEO Zed Guerry will lead the U.S. consumer health care business for Sanofi, reporting to Greg Irace, president and CEO of Sanofi-Aventis U.S. Soon after agreeing to acquire Chattem, Sanofi underscored its expanding consumer product focus by naming Hans Regenauer to head its global OTC business (2"The Tan Sheet" Jan. 11, 2010)

Related Content

Topics

UsernamePublicRestriction

Register

PS103692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel